Acne Therapeutics Market Report and Forecast 2025-2034
Description
The acne therapeutics market size was valued at USD 7.70 Billion in 2024, driven by the rising emphasis on improving facial aesthetics across the major markets. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034, with the values likely to rise from USD 12.07 Billion by 2034.
Acne Therapeutics Market Overview
The prevalence of acne is around 80% in adolescents, however, adult acne is also on the rise, projected to affect nearly 40% of the global population. Around 20% of the acne patients experience moderate to severe acne. While it is not a life-threatening condition, acne comes with psychosocial baggage and may lead to psychological issues such as anxiety, low self-esteem, and even depression. Consequently, the emergence of new treatments with the integration of the latest technologies has become one of the major acne therapeutics market trends in recent years.
Acne therapeutics include topicals and drugs such as hormonal agents or antibiotics. The alternatives vary, based on age, type, and severity of the acne. Therapies like light therapy and chemical peels are also used in some conditions. The acne therapeutics market growth is driven by expediated drug development leading to subsequent growth in FDA approvals. There is an increased focus on offering better therapeutic solutions by merging the latest gene-based therapies with combination therapies.
Increasing Integration of Artificial Intelligence Based Therapeutics
To meet the rising acne therapeutics market demand, there has been growing application of latest technologies such as artificial intelligence to develop dermatology drugs. In November 2023, a biopharmaceutical company, Almirall, with dermatology as a major domain and Absci Corporation, a generative artificial intelligence drug creation company collaborated to offer customized medicines by incorporating AI.
Rising Emphasis on Combating Antibiotic Resistance
Antibiotics for acne treatment have also been a major area of interest amongst researchers. However, broad spectrum antibiotics target both good as well as bad bacteria and antibiotic resistance, which is another key constraint that has emerged in recent years. Therefore, there is ongoing research for effective alternatives leading to substantial growth in the acne therapeutics market share.
A new Yale study, published in March 2023, examined the role of third generation of tetracycline derivative Sarecycline which directly targets Cutibacterium acnes and other gram-positive bacteria, mostly responsible for causing acne. This derivative has gained high prevalence owing to its structural competence over others, which limits the chances of mutation, therefore, opposing antibiotic resistance.
Growth in the Incidence of FDA Approvals to be a Key Driver for Market Demand
The acne therapeutics market growth is driven by increasing drug development activity and marketing authorizations by regulatory bodies. In October 2023, the FDA approved Cabtreo (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%), which is a triple-combination topical treatment for acne. Developed by Bausch Health Companies Inc. and their dermatology business Ortho Dermatologics, this treatment combines the action mechanism of an antibiotic, retinoid and antibacterials. Isotretinoin is another high-dose vitamin A medication that shrinks sebaceous glands along with getting rid of breakout causing bacteria.
In April 2023, Dermata Therapeutics also received a positive response for initiating phase III studies for evaluating their latest once-a-week topical acne treatment DMT310. Derived from naturally sourced freshwater sponge, this drug is also being studied to treat rosacea and psoriasis. To expand their product line, the company is working towards developing a new candidate DMT410, that will employ a needle free intradermal administration of botulinum toxin to treat various aesthetic and medical skin conditions. Consequently, the acne therapeutics market size is expected to grow with ongoing advancements in the pharmaceutical domain.
Acne Therapeutics Market Segmentation
Acne Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Injury Type Retinoid
Antibiotics
Hormonal Agents
Anti-inflammatory
Other Agents Germany
France
Italy
Spain
Acne is the most common skin condition in the United States, affecting approximately 3 million people every year. So, the United States is anticipated to lead the acne therapeutics market share. The emphasis on product line expansion is a vital aspect of the market size. In October 2023, Crown Therapeutics unveiled two new products in their dermatologist backed award winning product line. PanOxyl Clarifying Exfoliant with 2% Salicylic Acid and PanOxyl Adapalene 0.1% Gel are clinically proven to treat acne with their high-performance ingredients.
Europe is another key player of the market with hefty investments occurring in various key conditions. In March 2023, a Swedish pharmaceutical company, Vakona, received USD 13.4 million investment from five investors to develop a new acne treatment drug. In addition, the presence of academic and research institutions is also a key aspect of growing market value.
The Asia Pacific acne therapeutics market value is expected to rise with increasing engagement of government and private sector companies to improve the healthcare infrastructure available in the region. In addition, there are several mergers and acquisitions occurring to offer better treatment alternatives to patients, which is fueling the market growth in the region.
Acne Therapeutics Market: Competitor Landscape
In December 2023, Eligo Bioscience, a gene-editing company, received a USD 30 million Series B funding by Sanofi Ventures for their flagship program EB005. This program is aimed at treating moderate to severe acne vulgaris with the application of in vivo gene-editing techniques. Such investments indicate the growing trend of using novel technologies to address diseases triggered by expression of bacterial genes.
The key features of the acne therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Acne Therapeutics Market Overview
The prevalence of acne is around 80% in adolescents, however, adult acne is also on the rise, projected to affect nearly 40% of the global population. Around 20% of the acne patients experience moderate to severe acne. While it is not a life-threatening condition, acne comes with psychosocial baggage and may lead to psychological issues such as anxiety, low self-esteem, and even depression. Consequently, the emergence of new treatments with the integration of the latest technologies has become one of the major acne therapeutics market trends in recent years.
Acne therapeutics include topicals and drugs such as hormonal agents or antibiotics. The alternatives vary, based on age, type, and severity of the acne. Therapies like light therapy and chemical peels are also used in some conditions. The acne therapeutics market growth is driven by expediated drug development leading to subsequent growth in FDA approvals. There is an increased focus on offering better therapeutic solutions by merging the latest gene-based therapies with combination therapies.
Increasing Integration of Artificial Intelligence Based Therapeutics
To meet the rising acne therapeutics market demand, there has been growing application of latest technologies such as artificial intelligence to develop dermatology drugs. In November 2023, a biopharmaceutical company, Almirall, with dermatology as a major domain and Absci Corporation, a generative artificial intelligence drug creation company collaborated to offer customized medicines by incorporating AI.
Rising Emphasis on Combating Antibiotic Resistance
Antibiotics for acne treatment have also been a major area of interest amongst researchers. However, broad spectrum antibiotics target both good as well as bad bacteria and antibiotic resistance, which is another key constraint that has emerged in recent years. Therefore, there is ongoing research for effective alternatives leading to substantial growth in the acne therapeutics market share.
A new Yale study, published in March 2023, examined the role of third generation of tetracycline derivative Sarecycline which directly targets Cutibacterium acnes and other gram-positive bacteria, mostly responsible for causing acne. This derivative has gained high prevalence owing to its structural competence over others, which limits the chances of mutation, therefore, opposing antibiotic resistance.
Growth in the Incidence of FDA Approvals to be a Key Driver for Market Demand
The acne therapeutics market growth is driven by increasing drug development activity and marketing authorizations by regulatory bodies. In October 2023, the FDA approved Cabtreo (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%), which is a triple-combination topical treatment for acne. Developed by Bausch Health Companies Inc. and their dermatology business Ortho Dermatologics, this treatment combines the action mechanism of an antibiotic, retinoid and antibacterials. Isotretinoin is another high-dose vitamin A medication that shrinks sebaceous glands along with getting rid of breakout causing bacteria.
In April 2023, Dermata Therapeutics also received a positive response for initiating phase III studies for evaluating their latest once-a-week topical acne treatment DMT310. Derived from naturally sourced freshwater sponge, this drug is also being studied to treat rosacea and psoriasis. To expand their product line, the company is working towards developing a new candidate DMT410, that will employ a needle free intradermal administration of botulinum toxin to treat various aesthetic and medical skin conditions. Consequently, the acne therapeutics market size is expected to grow with ongoing advancements in the pharmaceutical domain.
Acne Therapeutics Market Segmentation
Acne Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Injury Type
- Complete Acne Therapeutics
- Incomplete Acne Therapeutics
- Therapeutics
- Other Treatments
- Oral
- Topical
- Others
- Hospitals
- Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Japan
Acne is the most common skin condition in the United States, affecting approximately 3 million people every year. So, the United States is anticipated to lead the acne therapeutics market share. The emphasis on product line expansion is a vital aspect of the market size. In October 2023, Crown Therapeutics unveiled two new products in their dermatologist backed award winning product line. PanOxyl Clarifying Exfoliant with 2% Salicylic Acid and PanOxyl Adapalene 0.1% Gel are clinically proven to treat acne with their high-performance ingredients.
Europe is another key player of the market with hefty investments occurring in various key conditions. In March 2023, a Swedish pharmaceutical company, Vakona, received USD 13.4 million investment from five investors to develop a new acne treatment drug. In addition, the presence of academic and research institutions is also a key aspect of growing market value.
The Asia Pacific acne therapeutics market value is expected to rise with increasing engagement of government and private sector companies to improve the healthcare infrastructure available in the region. In addition, there are several mergers and acquisitions occurring to offer better treatment alternatives to patients, which is fueling the market growth in the region.
Acne Therapeutics Market: Competitor Landscape
In December 2023, Eligo Bioscience, a gene-editing company, received a USD 30 million Series B funding by Sanofi Ventures for their flagship program EB005. This program is aimed at treating moderate to severe acne vulgaris with the application of in vivo gene-editing techniques. Such investments indicate the growing trend of using novel technologies to address diseases triggered by expression of bacterial genes.
The key features of the acne therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Cipher Pharmaceuticals
- GlaxoSmithKline PLC
- L'Oréal S.A. (La Roche-Posay Laboratoire Dermatologique)
- Teva Pharmaceuticals
- Sun Pharmaceuticals
- Abbvie Inc.
- F. Hoffmann-la Roche Ltd
- Viatris Inc.
- Johnson & Johnson
- Bausch Health Companies Inc.
- Perricone MD
- Glow Biotics LLC
- Revision Skincare
- The Beauty Health Company
- PHYTOMER
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Acne Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Acne Epidemiology Analysis – Seven Major Markets
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Acne Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Acne Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Acne Epidemiology Forecast (2018-2034)
- 5.3.2 France Acne Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Acne Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Acne Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Acne Epidemiology Forecast (2018-2034)
- 5.4 Japan Acne Epidemiology Forecast (2018-2034)
- 6 Acne Therapeutics Market Overview – 7MM
- 6.1 Acne Therapeutics Market Historical Value (2018-2024)
- 6.2 Acne Therapeutics Market Forecast Value (2025-2034)
- 7 Acne Therapeutics Market Landscape – 7MM
- 7.1 Acne Therapeutics: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Acne Therapeutics: Product Landscape
- 7.2.1 Analysis by Injury Type
- 7.2.2 Analysis by Route of Administration
- 8 Acne Therapeutics Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Acne Therapeutics Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Acne Therapeutics Market Segmentation – Seven Major Markets
- 11.1 Acne Therapeutics Market by Injury Type
- 11.1.1 Market Overview
- 11.1.2 Complete Acne Therapeutics
- 11.1.3 Incomplete Acne Therapeutics
- 11.2 Acne Therapeutics Market by Treatment Type
- 11.2.1 Market Overview
- 11.2.2 Therapeutics
- 11.2.2.1 Retinoid
- 11.2.2.2 Antibiotics
- 11.2.2.3 Hormonal Agents
- 11.2.2.4 Anti-inflammatory
- 11.2.2.5 Other Agents
- 11.2.3 Other Treatments
- 11.3 Acne Therapeutics Market by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Topical
- 11.3.4 Others
- 11.4 Acne Therapeutics Market by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Clinics
- 11.4.4 Others
- 11.5 Acne Therapeutics Market by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.6 Japan
- 12 United States Acne Therapeutics Market
- 12.1 Acne Therapeutics Market Historical Value (2018-2024)
- 12.2 Acne Therapeutics Market Forecast Value (2025-2034)
- 12.2.1 Acne Therapeutics Market by Injury Type
- 12.2.2 Acne Therapeutics Market by Treatment Type
- 13 EU-4 and United Kingdom Acne Therapeutics Market
- 13.1 Acne Therapeutics Market Historical Value (2018-2024)
- 13.2 Acne Therapeutics Market Forecast Value (2025-2034)
- 13.3 Germany Acne Therapeutics Market Overview
- 13.3.1 Acne Therapeutics Market by Injury Type
- 13.3.2 Acne Therapeutics Market by Treatment Type
- 13.4 France Acne Therapeutics Market Overview
- 13.4.1 Acne Therapeutics Market by Injury Type
- 13.4.2 Acne Therapeutics Market by Treatment Type
- 13.5 Italy Acne Therapeutics Market Overview
- 13.5.1 Acne Therapeutics Market by Injury Type
- 13.5.2 Acne Therapeutics Market by Treatment Type
- 13.6 Spain Acne Therapeutics Market Overview
- 13.6.1 Acne Therapeutics Market by Injury Type
- 13.6.2 Acne Therapeutics Market by Treatment Type
- 13.7 United Kingdom Acne Therapeutics Market Overview
- 13.7.1 Acne Therapeutics Market by Injury Type
- 13.7.2 Acne Therapeutics Market by Treatment Type
- 14 Japan Acne Therapeutics Market
- 14.1 Acne Therapeutics Market Historical Value (2018-2024)
- 14.2 Acne Therapeutics Market Forecast Value (2025-2034)
- 14.2.1 Acne Therapeutics Market by Injury Type
- 14.2.2 Acne Therapeutics Market by Treatment Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4 JAPAN PMDA
- 15.1.5 Others
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Cipher Pharmaceuticals
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 GlaxoSmithKline PLC
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 L'Oréal S.A. (La Roche-Posay Laboratoire Dermatologique)
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Teva Pharmaceuticals
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Sun Pharmaceuticals
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Abbvie Inc.
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 F. Hoffmann-la Roche Ltd
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Viatris Inc.
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Johnson & Johnson
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Bausch Health Companies Inc.
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Perricone MD
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Glow Biotics LLC
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Revision Skincare
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 The Beauty Health Company
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 PHYTOMER
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Acne Therapeutics - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
